RBC Capital Remains a Buy on HCA Healthcare (HCA)
RBC Capital analyst Ben Hendrix maintained a Buy rating on HCA Healthcare on February 17 and set a price target of $593.00. The company’s shares closed yesterday at $534.78.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hendrix covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, CVS Health, and Tenet Healthcare. According to TipRanks, Hendrix has an average return of 5.2% and a 51.86% success rate on recommended stocks.
In addition to RBC Capital, HCA Healthcare also received a Buy from Mizuho Securities’s Ann Hynes in a report issued on February 2. However, on February 9, Bernstein maintained a Hold rating on HCA Healthcare (NYSE: HCA).
Based on HCA Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $19.51 billion and a net profit of $1.88 billion. In comparison, last year the company earned a revenue of $18.29 billion and had a net profit of $1.44 billion
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year. Earlier this month, Christopher F. Wyatt, the SVP & Controller of HCA sold 5,034.00 shares for a total of $2,539,119.70.
Read More on HCA:
Disclaimer & DisclosureReport an Issue
- MSFT Stock in the Spotlight as Microsoft Builds Its Own AI Model and Targets Healthcare
- HCA Healthcare Faces Rising Hurricane Risk Despite Insurance, Threatening Operations and Earnings
- HCA Healthcare price target raised to $541 from $503 at Bernstein
- HCA Healthcare price target raised to $540 from $520 at Mizuho
- HCA Healthcare price target raised to $481 from $452 at Wells Fargo
